Clinical Report: Persistence and Utilization of Long-Acting Injectable Cabotegravir
Overview
This study examines the uptake and persistence of long-acting injectable cabotegravir (LAI-CAB) as a pre-exposure prophylaxis (PrEP) option in the US from 2022 to 2024. By the end of 2023, LAI-CAB accounted for only 2.5% of US PrEP users.
Background
HIV continues to pose a significant public health challenge in the US, with over 38,000 new diagnoses projected in 2024. LAI-CAB, approved in December 2021, is an alternative to daily oral PrEP, with clinical trials indicating efficacy in reducing HIV infection risk.
Data Highlights
No numerical data is provided in the source material.
Key Findings
LAI-CAB was the only LAI-PrEP option from 2022 to 2024.
By the end of 2023, LAI-CAB represented only 2.5% of US PrEP users.
Preferences for LAI-CAB over oral PrEP ranged from 52% to 81% among eligible participants.
Barriers to LAI-CAB uptake include medication acquisition, logistics, and insurance complexities.
Persistence analyses distinguish between LAI-CAB use and any PrEP modality use.
Clinical Implications
Healthcare providers should be aware of barriers affecting the uptake of LAI-CAB, including logistical and insurance-related challenges.
Conclusion
The findings indicate a gap between interest in LAI-CAB and its actual uptake.
by Shi Hao Ernest Koh, Wenting Huang, Eric W. Hall, Jeb Jones, Xiao Zang, Courtney R. Yarbrough, Edwin E. Corbin-Gutierrez, Patrick S. Sullivan, Aaron J. Siegler
